Pomalidomide 4'-PEG2-azide

Background Introduction

Pomalidomide 4'-PEG2-azide is a versatile bifunctional molecule designed for use in targeted protein degradation studies, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). It features a pomalidomide moiety, which serves as a ligand for recruiting the cereblon (CRBN) E3 ubiquitin ligase, combined with a PEG2-azide linker that allows rapid and flexible conjugation to various target-binding ligands. This reagent is widely used by researchers exploring next-generation therapeutics for cancer, neurological disorders, and other diseases.

Mechanism

Pomalidomide 4'-PEG2-azide operates by exploiting the ubiquitin-proteasome system, the cell’s natural protein degradation pathway. The pomalidomide portion of the molecule selectively binds to the CRBN E3 ubiquitin ligase, one of the major E3 ligases leveraged in PROTAC design. The PEG2-azide linker enables click chemistry-based attachment to other molecular modules, such as target protein binders or fluorophores. When incorporated into a PROTAC, this conjugate bridges the target protein and CRBN, facilitating the ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Pomalidomide 4'-PEG2-azide is primarily used as a building block in PROTAC synthesis, accelerating the development of custom protein degraders for drug discovery. Its azide-functionalized linker is amenable to Copper(I)-catalyzed Azide-Alkyne Cycloaddition (CuAAC) or other click chemistry-based conjugations, streamlining the assembly of bifunctional molecules. Researchers utilize this product for generating a wide range of PROTACs aimed at degrading therapeutically relevant proteins, investigating cellular mechanisms, and validating new drug targets. Additionally, it serves as a valuable tool in chemical biology for labeling and tracking proteins in live-cell imaging and proximity labeling experiments.

Pomalidomide 4'-PEG2-azide serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, enhancing targeted protein degradation through its efficient binding and degradation capabilities. The following provides a detailed description of this molecule, including its linker, ligand, and the selection of target protein ligands.

Linker: The linker in Pomalidomide 4'-PEG2-azide is a PEG2 chain, offering moderate length and flexibility to optimize spatial orientation. Its flexible nature facilitates the efficient bridging of the ligand and target protein, while the azide moiety allows for bio-orthogonal reactions, enhancing cleavability and adaptability in diverse environments.

Ligand: The ligand component is derived from pomalidomide, a well-characterized thalidomide analog. This ligand exhibits a robust binding affinity to the cereblon E3 ubiquitin ligase complex, facilitating the recruitment of the target protein for ubiquitination and subsequent proteasomal degradation.

Reactive Site: The azide group in the molecule serves as a reactive site, coupling effectively with alkyne-containing target protein ligands through click chemistry reactions. This approach ensures high specificity and efficiency in conjugating the ligand to the target protein, enabling precise degradation.

Recommended Target Protein Ligand: Alkyne-functionalized warheads are highly compatible with Pomalidomide 4'-PEG2-azide, offering the advantage of stable and selective conjugation through click chemistry. These warheads can be tailored to target specific proteins, facilitating the degradation of disease-relevant proteins in experimental studies. This compatibility enables researchers to explore diverse protein targets, expanding the potential applications of PROTAC technology.